Usefulness and safety of 0.4% sodium hyaluronate solution as a submucosal fluid

Table 6 Adverse events

All Patients (n = 41)	patients
Patients with adverse events	19	[4]	(2)
Adverse events occurring in ≥ 2 patients^†
Abdominal pain	4	[1]	(0)
Post procedural haemorrhage^‡	4	[2]	(2)
Haemorrhage during procedure^‡	3	[0]	(0)
Vomiting	2	[0]	(0)
Diarrhoea	2	[0]	(0)
Insomnia	2	[0]	(0)
Intestinal perforation	1	[1]	(0)

All patients who had used 0.4% sodium hyaluronate (SH) were analyzed for adverse events. The square bracket shows the number of patients with serious adverse events. The parenthesis shows the number of patients with adverse events that were judged to be related to 0.4% SH.
† Although one patient experienced intestinal perforation, this event was defined to be a serious adverse event. Therefore, it was added in this table.
‡ Bleeding was defined as the use of clipping or another treatment to stop or prevent bleeding as well as the incidence of actual bleeding.

ISSN: 1471-230X